Therapeutic management of erectile dysfunction: The AFU/SFMS guidelines.

Context: Erectile dysfunction (ED) is a common sexual disorder. In France, recent evidence-based guidelines are lacking.

Aim: To provide practice guidelines on ED therapeutic management.

Evidence Acquisition: Publications indexed in PubMed/Medline® between January 1999 and October 2023, were reviewed. For each clinical question, a level of evidence was attributed to the conclusions. These conclusions and the working group arguments were used to develop and grade (A-C) the recommendations.

Recommendations: ED management must be personalized. Phosphodiesterase 5 inhibitors (PDE5I) are recommended as first-line treatment (A). In patients with severe ED, a combination of PDE5I may be proposed as first- or second-line treatment (Expert Agreement, EA). Extra-cavernous or intra-urethral injections of alprostadil may be offered as first-line alternative to PDE5I or as second-line treatment (B). In case of unsatisfactory response to PDE5I or alprostadil alone, the combination of a PDE5I with intra-cavernosal or intra-urethral alprostadil may be proposed (EA). Vacuum therapy can be offered to all patients (B). Low-intensity extracorporeal shockwave therapy may be proposed to patients with mild or moderate ED, alone or in combination with PDE5I (B). Penile implants are indicated for patients with ED who are refractory or intolerant to pharmacological or mechanical treatments, or if they wish a permanent solution (B). Revascularization surgery may be offered to patients without comorbidities following pelvic trauma and ED with isolated arterial insufficiency (B). In addition to pharmaceutical, mechanical and/or surgical treatments, it is suggested to always consider educational interventions and counseling, lifestyle modifications and management of co-morbidities and curable causes.